Document is current
Any future updates will be listed below
-
Authors
Beck, David B. https://orcid.org/0000-0002-5884-6231
Georgin-Lavialle, Sophie https://orcid.org/0000-0001-6668-8854
Kirino, Yohei https://orcid.org/0000-0002-9488-661X
Patel, Bhavisha A.
Ferrari, Samuele https://orcid.org/0000-0003-1122-1231
- License Information
-
More Information
Article History
Accepted: 12 March 2026
First Online: 16 April 2026
Competing interests
: D.B.B. is a consultant for GSK, Sobi, Novartis, Alexion and Genesis Therapeutics. S.G.-L. receives speaking and expertise fees from Novartis and Sobi. Y.K. receives speaking fees from Novartis, Amgen and consultation fees from Sobi, Novartis. S.F. is an inventor on a patent on methods and means of UBA1 genetic modification for VEXAS syndrome (inventors: S.F., M. Fiumara, L. Naldini, R. Molteni, G. Cavalli; patent no. WO/2025/088508A1; status pending) jointly owned and managed by IRCCS San Raffaele Scientific Institute and Fondazione Telethon ETS. B.A.P. declares no competing interests.
: The authors affirm that human research participants provided informed consent for publication of the images in Fig. .
